FDA Approves Spray To Treat Menopause Symptoms

Armen Hareyan's picture

Mountain View, Calif.-based pharmaceutical company Vivus on Monday announced it received FDA approval for a spray to treat hot flashes and other moderate to severe menopause-related symptoms, the San Jose Mercury News reports. The spray, called EvaMist, delivers a measured dose of estrogen to a woman's skin (Johnson, San Jose Mercury News, 7/31).


St. Louis-based KV Pharmaceutical,which bought the marketing rights for EvaMist earlier this year, willpay $140 million to Vivus under an agreement reached between the twocompanies, Reuters reports. KV intends to launch the product during the second half of fiscal year 2008 (Relia/Tickoo, Reuters, 7/30).

According to the Mercury News,Vivus executives said EvaMist can be used to treat hot flashes withlower doses of estrogen than other products on the market (San Jose Mercury News,7/31). Marc Hermelin, KV board chair and CEO, said, "We believe ourexisting presence in the women's health market and our specializedfocus on the ob-gyn community through our dedicated sales force willallow us to successfully promote the benefits of EvaMist to physiciansand patients" (KV Pharmaceutical release, 7/30).

Reprinted with permission from kaisernetwork\t\t\t\t\t\t\t

Reprinted with permission fromkaisernetwork.org.You can view the entire KaiserDaily Women's Health Policy Report, search thearchives, and sign up for email delivery at kaisernetwork.org/email. The Kaiser Daily Women's Health Policy Report is published forkaisernetwork.org,a free service of The Henry J. Kaiser Family Foundation.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.